James W. Lynch

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

Lawrence D. Piro, Christine A. White, A.J. Grillo-López et al. · Annals of Oncology · 1999 · 368 citations · Full text

Life Sciences, Immunology, Oncology +13

Phase II Trial of Individualized Rituximab Dosing for Patients With CD20-Positive Lymphoproliferative Disorders

Lucio Gordan, William B. Grow, Annette Pusateri et al. · Journal of Clinical Oncology · 2005 · 123 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +15

Poor Mobilization of Peripheral Blood Stem Cells is a Risk Factor for Worse Outcome in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Lucio Gordan, Michele W. Sugrue, James W. Lynch et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2003 · 94 citations

Medicine, Hematology, Oncology +17

The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin’s lymphoma

Sachin S. Kamath, Robert B. Marcus, James W. Lynch et al. · International Journal of Radiation Oncology*Biology*Physics · 1999 · 75 citations

Medicine, Oncology, Radiation Oncology +17

Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma

Lucio Gordan, Michele W. Sugrue, James W. Lynch et al. · Bone Marrow Transplantation · 2003 · 74 citations

Medicine, Hematology, Immunology +14